Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
Conditions
Keywords
clinical, pharmacodynamics, investigational drug clofarabine, AML, ALL, CML-accelerated phase, CML-blastic phase, Chronic Myelogenous Leukemia - accelerated phase, Chronic Myelogenous Leukemia - blastic phase
Brief summary
The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic phases.
Detailed description
The specific aims of the project are (1) conduct the phase II study of clofarabine and evaluate the antileukemic efficacy in AML, ALL, and CML-accelerated and blastic phases in terms of complete response (CR) rate, response duration, and survival; and (2) analyze the relationship between cellular uptake and retention of clofarabine triphosphate (the active metabolite), inhibition of DNA synthesis, and clinical outcome. Completion date provided represents the completion date of the grant per OOPD records
Interventions
DRUGclofarabine
Sponsors
University of Texas
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is diagnosed with AML, ALL, myelodysplastic syndrome (MDS), and CML in transformation (includes CML-blastic phase and CML-accelerated phase). * No prior chemo-, immuno-, or radio-therapy for 2 weeks before entering the study, unless progressive life-threatening leukemia as judged by the treated physician. * Adequate liver function (bilirubin \</= 2 mg%) and renal function (creatinine \</= 2 mg%). * Pregnant and lactating females not eligible. * Zubrod performance status 0-2 * Adequate cardiac status * No life-threatening conditions (e.g. infections) which may cause death within 3 weeks.
Outcome results
None listed